Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 2/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | CTPS1 | P17812 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30044126 | 0.99 | HSD11B1 (1.00) | HSD11B1HSD17B1HSD17B2F2F10 | |
| Hydrochloric Acid SCHEMBL5692696 | 0.99 | HSD11B1 (1.00) | HSD11B1HSD17B1HSD17B2F2F10 | |
| Trifluoroacetic Acid SCHEMBL3619340 | 0.94 | HSD11B1 (0.89) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL3616863 | 0.93 | HSD11B1 (0.86) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL3606652 | 0.93 | HSD11B1 (0.86) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL16325423 | 0.92 | HSD11B1 (0.85) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL3616943 | 0.92 | HSD11B1 (0.84) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL3614188 | 0.91 | HSD11B1 (0.83) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5692940 | 0.90 | HSD11B1 (0.82) | HSD11B1HSD17B1HSD17B2F2F10 | |
| SCHEMBL3615493 | 0.90 | HSD11B1 (0.82) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137209-A1 | Treatment of neurologic disorders with inhibitors of 11beta-HSD1 | AGY THERAPEUTICS, INC. | 2005-06-23 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4381284-B1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZUERICH (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | SPARROW PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240293375-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-05 | — | — | US | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039171-A1 | 4-OXY-N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039176-A1 | DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20050186659-A1 | Methods for protein purification | BIOVITRUM AB (SE) | 2005-08-25 | — | — | US | disclosed |
| US-20050137209-A1 | Treatment of neurologic disorders with inhibitors of 11beta-HSD1 | AGY THERAPEUTICS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293375-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 4/4885 |
| US-20050137209-A1 | Treatment of neurologic disorders with inhibitors of 11beta-HSD1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 7/4885 |
| US-20250319072-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 4/4885 |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885HSD17B1 7/4885HSD17B2 13/4885 |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885HSD17B1 10/4885HSD17B2 12/4885 |
| US-12329745-B2 | Methods and compositions for treating glucocorticoid excess | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 4/4885 |
| US-20260137660-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | HSD11B1 4/4885HSD17B1 9/4885HSD17B2 11/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | HSD11B1 4/4885HSD17B1 13/4885HSD17B2 20/4885 |
| US-20260137658-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, NR5A1 | HSD11B1 5/4885HSD17B1 7/4885HSD17B2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.